SCHEMBL6267293

SCHEMBL6267293

O=C(O)CCCn1c(=O)c(C2=NS(=O)(=O)c3ccccc3N2)c(O)c2ccccc21

nearest known ligand 0.75

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.68
MAPK1 P28482 2/20 0.68
CYP2C9 P11712 3/20 0.57
NR1I2 O75469 1/20 0.57
FABP4 P15090 2/20 0.46
FABP5 Q01469 2/20 0.46
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 6/20 0.43
MAPT P10636 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.41
GAA P10253 2/20 0.41
RCE1 Q9Y256 1/20 0.38
CTNNB1 P35222 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6211629 0.89 HSD17B10 (0.72) HSD17B10MAPK1CYP2C9NR1I2ALDH1A1
SCHEMBL6235919 0.89 HSD17B10 (0.68) HSD17B10MAPK1CYP2C9NR1I2ALDH1A1
SCHEMBL8239358 0.88 HSD17B10 (0.74) HSD17B10MAPK1CYP2C9NR1I2ALDH1A1
SCHEMBL6732624 0.88 HSD17B10 (0.71) HSD17B10MAPK1CYP2C9NR1I2ALDH1A1
SCHEMBL6209102 0.87 MAPK1 (0.65) HSD17B10MAPK1CYP2C9NR1I2ALDH1A1
SCHEMBL6238046 0.87 HSD17B10 (0.72) HSD17B10MAPK1CYP2C9NR1I2ALDH1A1
SCHEMBL6739989 0.87 HSD17B10 (0.74) HSD17B10MAPK1CYP2C9NR1I2ALDH1A1
SCHEMBL6235728 0.86 HSD17B10 (0.68) HSD17B10MAPK1CYP2C9NR1I2ALDH1A1
SCHEMBL6736757 0.86 HSD17B10 (0.70) HSD17B10MAPK1CYP2C9NR1I2ALDH1A1
SCHEMBL6235081 0.86 HSD17B10 (0.67) HSD17B10MAPK1CYP2C9NR1I2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401443-A4 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORP (US) 2005-10-26 EP claimed
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US claimed
EP-1401443-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2004-03-31 EP claimed
WO-2002098424-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2002-12-12 WO claimed
EP-1401443-A4 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORP (US) 2005-10-26 EP disclosed
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US disclosed
EP-1401443-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2004-03-31 EP disclosed
WO-2002098424-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147739-A1 Novel anti-infectives RPL5, RPL7, RPL35 HSD17B10 1428/4885MAPK1 3699/4885CYP2C9 1218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.